Chaim Lebovits, BrainStorm CEO
After rare public brushback, FDA again turns away BrainStorm's ALS drug with RTF letter
As a cell therapy biotech developing a new treatment for ALS attempted to approach the FDA with its application, it found the agency’s doors slammed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.